Trans-arterial Radio-embolization: a New Chance for Patients with Hepatocellular Cancer to Access Liver Transplantation, a World Review

Overview

Journal Transl Gastroenterol Hepatol

Publisher AME Publishing Company

Specialty Gastroenterology

Date 2017 Dec 22

PMID 29264436

Citations 11

Authors

Giovanni Battista Levi Sandri

Giuseppe Maria Ettorre

Valerio Giannelli

Marco Colasanti

Rosa Sciuto

Giuseppe Pizzi

Roberto Cianni

Gianpiero DOffizi

Mario Antonini

Giovanni Vennarecci

Pierleone Lucatelli

Affiliations

Soon will be listed here.

Abstract

Liver transplantation (LT) for hepatocellular carcinoma (HCC) within the Milan criteria (MC) is nowadays a curative procedure. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. The aim of this work is to offer a view on the publications which report on the use of Y90-RE as bridge or downstaging prior to LT. Twenty articles have been considered for this world review. About 178 LT in patients were treated with Y90-RE prior to LT. Most of patients had a downstaging strategy. In all series alpha-fetoproteins decreased between Y90-RE and LT. Therefore, Y90-RE may have an important role in the bridge and downstaging treatments.

Citing Articles

Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report.

Zhang J, Yu Z, Li H, Yi S, Liu W, Yang Y Liver Res. 2025; 5(1):33-35.

PMID: 39958925 PMC: 11791838. DOI: 10.1016/j.livres.2020.10.002.

Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging.

Zeimpekis K, Sari H, Gozlugol N, Achangwa N, Shi K, Schindewolf M Eur J Nucl Med Mol Imaging. 2024; 52(4):1460-1471.

PMID: 39730786 PMC: 11839895. DOI: 10.1007/s00259-024-07034-9.

Liver transplantation for hepatocellular carcinoma in India: Are we ready for 2040?.

Pahari H, Raj A, Sawant A, Ahire D, Rathod R, Rathi C World J Transplant. 2024; 14(1):88833.

PMID: 38576752 PMC: 10989470. DOI: 10.5500/wjt.v14.i1.88833.

Y post-radioembolization clinical assessment with whole-body Biograph Vision Quadra PET/CT: image quality, tumor, liver and lung dosimetry.

Zeimpekis K, Mercolli L, Conti M, Sari H, Rominger A, Rathke H Eur J Nucl Med Mol Imaging. 2024; 51(7):2100-2113.

PMID: 38347299 PMC: 11139701. DOI: 10.1007/s00259-024-06650-9.

Phantom-based evaluation of yttrium-90 datasets using biograph vision quadra.

Zeimpekis K, Mercolli L, Conti M, Sari H, Prenosil G, Shi K Eur J Nucl Med Mol Imaging. 2022; 50(4):1168-1182.

PMID: 36504278 PMC: 9931793. DOI: 10.1007/s00259-022-06074-3.

References

Ettorre G, Levi Sandri G, Laurenzi A, Colasanti M, Meniconi R, Lionetti R . Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg. 2016; 41(1):241-249. DOI: 10.1007/s00268-016-3682-z. View

Luna L, Kwo P, Roberts L, Mettler T, Gansen D, Andrews J . Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol. 2009; 6(11):679-83. PMC: 2904913. DOI: 10.1038/nrgastro.2009.165. View

Tohme S, Sukato D, Chen H, Amesur N, Zajko A, Humar A . Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. 2013; 24(11):1632-8. DOI: 10.1016/j.jvir.2013.07.026. View

Nicolay N, Berry D, Sharma R . Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009; 6(12):687-97. DOI: 10.1038/nrclinonc.2009.165. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S . Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011; 54(3):868-78. DOI: 10.1002/hep.24451. View

Ettorre G, Santoro R, Puoti C, Sciuto R, Carpanese L, Antonini M . Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. Transplantation. 2010; 90(8):930-1. DOI: 10.1097/TP.0b013e3181f10f04. View

Yao F, Hirose R, LaBerge J, Davern 3rd T, Bass N, Kerlan Jr R . A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005; 11(12):1505-14. DOI: 10.1002/lt.20526. View

Raoul J, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L . Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2010; 37(3):212-20. DOI: 10.1016/j.ctrv.2010.07.006. View

10.

Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D . Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology. 2013; 58(5):1655-66. PMC: 5097874. DOI: 10.1002/hep.26487. View

11.

Sato K, Lewandowski R, Bui J, Omary R, Hunter R, Kulik L . Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006; 29(4):522-9. DOI: 10.1007/s00270-005-0171-4. View

12.

Yao F, Kerlan Jr R, Hirose R, Davern 3rd T, Bass N, Feng S . Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48(3):819-27. PMC: 4142499. DOI: 10.1002/hep.22412. View

13.

Yao F, Ferrell L, Bass N, Watson J, Bacchetti P, Venook A . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6):1394-403. DOI: 10.1053/jhep.2001.24563. View

14.

Vouche M, Habib A, Ward T, Kim E, Kulik L, Ganger D . Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014; 60(1):192-201. DOI: 10.1002/hep.27057. View

15.

Bolondi L, Burroughs A, Dufour J, Galle P, Mazzaferro V, Piscaglia F . Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2013; 32(4):348-59. DOI: 10.1055/s-0032-1329906. View

16.

Heckman J, Devera M, Marsh J, Fontes P, Amesur N, Holloway S . Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008; 15(11):3169-77. DOI: 10.1245/s10434-008-0071-3. View

17.

Ettorre G, Levi Sandri G, Santoro R, Lepiane P, Colasanti M, Vennarecci G . Bridging and downstaging to transplantation in hepatocellular carcinoma. Future Oncol. 2014; 10(15 Suppl):61-3. DOI: 10.2217/fon.14.226. View

18.

Khalaf H, Alsuhaibani H, Al-Sugair A, Al-Mana H, Al-Mutawa A, Al-Kadhi Y . Use of yttrium-90 microsphere radioembolization of hepatocellular carcinoma as downstaging and bridge before liver transplantation: a case report. Transplant Proc. 2010; 42(3):994-8. DOI: 10.1016/j.transproceed.2010.03.019. View

19.

Barakat O, Patrick Wood R, Ozaki C, Ankoma-Sey V, Galati J, Skolkin M . Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl. 2010; 16(3):289-99. DOI: 10.1002/lt.21994. View

20.

Lei J, Wang W, Yan L . Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg. 2013; 17(8):1440-6. DOI: 10.1007/s11605-013-2229-y. View